Hybrid Fractional Laser Treatment for Symptoms of Urinary Incontinence

Sciton51 enrolled

Overview

This multi-center clinical trial will evaluate the safety and long-term efficacy of hybrid fractional 2940 nm and 1470 lasers for improvement of symptoms of urinary incontinence.

Both 2940 nm Er:YAG (Erbium-doped yttrium aluminium garnet) and 1470 nm diode lasers are cleared by the Food and Drug Administration (FDA) for ablation, vaporization, coagulation of soft tissue and for skin resurfacing. Fractional delivery of laser is a well-established method that stimulates tissue remodeling in the dermis while leaving the surrounding tissue intact in order to decrease healing time. The layers of skin and vaginal mucosal tissue exhibit similarities that suggest the clinical results seen with skin resurfacing may be translated to the vaginal tissue. Improved vaginal tissue tone and increased collagen formation in the lamina propria beneath the urethra may lead to improved urinary control. This multi-centered, 18-month prospective clinical trial will determine the safety and long-term effectiveness of hybrid fractional 2940 nm and 1470 nm lasers (Hybrid Fractional Laser) as an alternative non-surgical, non-hormonal treatment for improvement of symptoms of urinary incontinence.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Urinary Incontinence Stress Urinary Incontinence Urge Incontinence

Interventions

Hybrid Fractional LaserDEVICE

Consecutive and coincident fractional 2940 nm and 1470 nm lasers

Eligibility

Sex: FEMALEMin age: 30 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Healthy biological female aged between 30 to 75 years 2. Is experiencing at least one or a combination of the following symptoms of urinary incontinence (UI) 1. involuntary urine leakage on effort, exertion, sneezing, coughing 2. sudden intense urge to urinate followed by involuntary loss of urine 3. Has been experiencing symptoms of UI for greater than 3 months 4. Normal urinalysis 5. Has indicated willingness to participate in the study by signing an informed consent form 6. Can read, understand and sign informed consent form 7. Agree to adhere to the treatment and follow-up schedule and post treatment care instructions Exclusion Criteria: 1. Undiagnosed abnormal genital bleeding 2. Has history of pelvic surgery or other energy-based vaginal therapy within 6 months prior to enrollment 3. Is pregnant or planning to get pregnant within the study period 4. Is currently breastfeeding 5. Has an active sexually transmitted infection (STI) 6. Has equal to or greater than stage III prolapse, according to pelvic organ prolapse quantification system (POP-Q test) 7. Has signs or symptoms of vaginitis/vulvitis 8. Has signs or symptoms of acute urinary tract infection (UTI) 9. Has voiding dysfunction or urinary retention 10. Has predominantly overactive bladder (OAB) as proven by urodynamics 11. Is currently taking medication for treating urinary incontinence 12. Has a known history of neurologic disease 13. Has history of heart failure 14. Any medical conditions that might interfere with wound healing 15. Has history of abnormal wound healing 16. Has participated in any clinical trial involving an investigational drug or procedure within past 30 days 17. The investigator feels that for any reason the subject is not eligible to participate in the study.

Locations (5)

Women's Pelvic Health Institute

Los Gatos, California, United States

Coyle Institute

Pensacola, Florida, United States

Carolinas Healthcare System

Charlotte, North Carolina, United States

Woodlands Gynecology & Aesthetics

The Woodlands, Texas, United States

Outcomes

Primary Outcomes

Change from baseline in Cough Stress Test

A diagnostic test to simulate accidental release of urine when the patient coughs.

Time frame: 14 months

Secondary Outcomes

Change from baseline in Incontinence Impact Questionnaire (IIQ-7)

A 7-item self-report instrument designed to assess the impact of urinary incontinence on a patient's life.

Time frame: 14 months

Change from baseline in Urogenital Distress Inventory (UDI-6)

A 6-item self-report instrument that assesses symptom distress and the impact on daily life of urinary incontinence.

Time frame: 14 months

Change from baseline in Female Sexual Function Index (FSFI)

A multidimensional self-report instrument for assessment of female sexual function.

Time frame: 14 months

Change from baseline in Histology

Change from baseline in epithelial thickness, collagen, elastin, vascularity, and fibroblast density.

Time frame: 14 months

Change from baseline in Urodynamic Testing

Quantitative measures of uroflowmetry, post-void residual (PVR) urine, cystometry, leak-point pressure, pressure flow, urethral pressure profile, and the functional urethral length.

Time frame: 14 months

Incidence and severity of treatment-related Adverse Events

Incidence and severity of treatment-related adverse events (i.e. pain, edema, erythema, altered sensation, scarring, and/or potential infection).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.